NOVELTY - A recombinant microorganism (m1) comprising heterologous nucleic acid encoding a modified chromatin modification related protein (YNG2) is new.    USE - For enhancing production of acetyl-CoA derived compound in a microorganism (claimed); for producing useful chemicals in more efficient and cost-effective quantities of the pharmaceutical, supplement, food and chemical industries. The chemicals are compounds derived from acetyl-CoA, such as, isoprenoids (used, in pharmaceutical products and as biofuels, food additives, and other specialty chemicals), amino acids (used, in feed additives and pharmaceutical products), fatty acids (used in in solvents, emulsifiers, cleaning compounds, and lubricants), and vitamins (used as dietary supplements).    ADVANTAGE - The recombinant microorganism accumulates a fatty acid product selected from palmitate, palmitoyl CoA, palmitoleic acid, sapienic acid, oleic acid, linoleic acid, alpha -linolenic acid, arachidonic acid, eicosapentaenoic acid, erucic acid, and docosahexaenoic acid. The microorganism produces increased amounts of acetyl-CoA derived compounds in industrial fermentation process.    DETAILED DESCRIPTION - INDEPENDENT CLAIMS are included for the following:    (1) a recombinant nucleic acid molecule comprising a polynucleotide encoding a modified YNG2;    (2) a vector comprising the nucleic acid molecule;    (3) a recombinant microorganism (m2) comprising heterologous nucleic acid encoding a YNG2 that is at least 95%, at least 90%, at least 85%, at least 75%, at least 65%, at least 55%, less than 90% identical to the wild-type YNG2 amino acid sequence (SEQ ID NO: 105) available on WIPO website or has at least 15%, has at least 25%, has at least 50%, has less than 50% decreased enzymatic activity relative to the wild-type YNG2 enzyme; and    (4) enhancing production (M1) of an acetyl-coenzyme A (CoA) derived compound in a microorganism involving: culturing the recombinant microorganism (m1) or (m2) in a suitable medium and under conditions that promote production of the acetyl-CoA derived compound, where the acetyl-CoA derived compound is produced at a level that is higher than the level of the acetyl-CoA derived compound in a microorganism not comprising the heterologous nucleic acid encoding a modified YNG2.